NCT00408499View on ClinicalTrials.gov

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

January 31, 2013

Conditions
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

cetuximab

Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.

DRUG

erlotinib

Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER

NCT00408499 - Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter